Hyaluronic Acid

In short: Hyaluronic acid (HA) is a natural glycosaminoglycan filler most commonly used in dermatology. Molecular weight and cross-linking level determine the rheology, regional suitability and duration of action of the products. Its effectiveness lasts 6-18 months and is reversible with hyaluronidase.

Description

Hyaluronic acid (HA, also hyaluronate, sodium hyaluronate) is a glucosaminoglycan biopolymer that occurs naturally in the body. Its chemical structure consists of β-1,4-D-glucuronic acid and β-1,3-N-acetyl-D-glucosamine disaccharide. HA used in dermal fillers is derived from biosynthetic or animal sources and is usually administered in sodium salt form. In aesthetic injections, the volumizing and hydration properties of HA fillers improve skin quality, elasticity and radiance. HA plays an important role in the extracellular matrix; It is found in high concentration in the skin dermat. During aging, HA production decreases and the concentration of HA in the extracellular matrix decreases by thirty to fifty percent; This contributes to skin dehydration, flakiness, lines and signs of aging. Dermal fillers compensate for the missing HA and restore skin hydration and volume.

Chemical Structure and Molecular Properties

Hyaluronic acid consists of a linear polysaccharide. Each repeating disaccharide unit has a molecular weight of four hundred Daltons. The natural HA chain can range from two hundred and fifty units to twenty-five thousand units. At physiological pH, HA is strongly negatively charged; This surface charge allows HA to attract water and interact with large amounts of water. One gram of HA can hold six liters of water. In the aesthetic filler industry, HA products are classified according to their molecular weight. Ultra-low (fifty to five hundred kilodaltons) is used in very thin, superficial fillers and its effect duration is between two and four months. Low molecular weight (five hundred to two thousand kilodaltons) medium fine HA includes products such as Restylane Light and Juvederm Volbella; It is useful for under-eye and lip filler. Medium molecular weight (two thousand to three thousand kilodaltons) is very common and includes products such as Juvederm Ultra and Restylane Lyft. High molecular weight (over three thousand kilodaltons) is the thickest HA and includes products such as Restylane Volume and Juvederm Voluma; Provides strong volumetricity and rigidity.

The biological activity of HA occurs through cellular receptors. CD44 is the major cellular receptor of the transmembrane glycoprotein HA; It is expressed by fibroblasts, keratinocytes, endothelial cells and macrophages. RHAMM (Receptor for Hyaluronic Acid-Mediated Motility) is a secondary receptor and plays a role in the regulation of cell migration and proliferation. HA-receptor engagement initiates signal transduction; It stimulates collagen and elastin synthesis, reduces inflammation and accelerates tissue healing. This mechanism explains the skin quality improvement and long-term anti-aging effects of dermal fillers.

The half-life of HA in the body varies depending on molecular weight, cross-linking and tissue localization. Pure, uncrosslinked HA has a half-life of twelve to twenty-four hours in the dermal layer. Cross-linked HA products persist longer; The dermal residence time of strongly cross-linked HA varies between three and six months. In contrast, HA survives longer in other tissues; For example, seventy days in vitreous humor, fifteen days in synovial fluid, a few minutes in blood serum. This difference is due to the dependence of HA on local enzyme activity and metabolic environment.

HA concentration in dermal tissue varies with age and skin health. HA concentration in young skin dermatitis ranges from 0.5 to 1 mg/mL; 4 mg/mL in vitreous humor; in joint fluid it is 1 to 4 mg/mL. With aging, dermal HA concentration decreases by twenty-five to thirty percent. This decrease is the main factors contributing to skin dehydration, loss of elasticity and age lines. Filler injections compensate for this missing HA and restore tissue turgor and hydration.

Cross-linking is critical. The pure HA chain is quickly broken down by the hyaluronidase enzyme in the body. For longer effect, HA chains are subjected to chemical cross-linking. BDDE cross-linking is patented by Allergan and is used in the Juvederm line; It forms solid and stable gels by connecting HA chains to each other in the outer structure. DVS cross-linking is used by Galderma in the Restylane series and provides a more elastic, mobile structure. Teoxane uses CPM (Coherent Polydensified Matrix) technology; Provides high cohesiveness with moderate cross-linking. Merz produces very soft and natural fillers using balanced crosslinking technology. Each crosslinking method provides a different rheological profile and clinical outcome.

Rheology parameters are the physical properties of HA fillers. G' (elastic modulus or storage modulus) measures the hardness and shape stability of the gel; It is expressed in Pascal (Pa) units. A high G' value means volumetric lifting capacity and structure resistance; For example, the G' value of Juvederm Voluma HMW is around 400-600 Pa, and Restylane Kysse is around 100-200 Pa. G'' (viscous modulus) measures the energy loss and fluidity of the gel. Tan delta (tg δ) is the ratio G'' divided by G' and shows the elastic-viscous balance of the gel. Low tan indicates delta elastic gel, high tan indicates delta viscous gel. Cohesiveness is measured in the Gavard-Sundaram test and shows the degree to which gel particles stay together and adhere to the tissue. Lift capacity measures how many times the HA gel can support its own weight; High lift capacity is preferred in deep volumetric fillers.

HA Filler Product Families and Contents

Juvederm is the most popular HA filler line made by Allergan. It uses BDDE cross-linking technology and ensures stability through the Vycross™ manufacturing process. Products of the series:

• Juvederm Volbella XC: Ultra-low molecular weight (500-1000 kDa), G' ~100 Pa, specially designed for lip contour and under-eye fine lines. Its effectiveness is 9-12 months.
• Juvederm Ultra XC: Medium molecular weight (1000-2000 kDa), G' ~200 Pa, multi-purpose use for lip filler, nasolabial fold and medium-fine lines. Its effectiveness is around 12 months.
• Juvederm Ultra Plus XC: High molecular weight (1500-2500 kDa), G' ~300 Pa, used for filler malar (cheeks), mandibular contour, chin definition and mid-depth lines. Its effectiveness is 12-15 months.
• Juvederm Volift XC: Medium-high molecular weight provides optimized, natural contour and lift to fill nasolabial folds and marian folds (lines). Its effectiveness is around 12 months.
• Juvederm Vollure XC: Medium-high molecular weight, designed to be used in dynamic lines (expression lines) and contour filler. It gives optimal results in combination with Botox.
• Juvederm Voluma XC: Ultra-high molecular weight (2000-3000+ kDa), G' ~400-600 Pa, designed for malar bone depth, gonial angle definition, chin volume and egg-shaped facial profile. Its effectiveness is 12-18 months; It has the strongest lift capacity.

Restylane is made by Galderma and uses DVS (Divinyl sulfone) cross-linking based on NASHA™ (Non-Animal Stabilized Hyaluronic Acid) and OBT™ (Optimized Balanced Technology) to provide natural movement:

• Restylane Silk: Ultra-low molecular weight serum-like, G' ~80 Pa, special for lip fine line filler and skin moisturizing. Its effectiveness is 6-9 months.
• Restylane Refyne: Low molecular weight, G' ~120 Pa, used in thin-medium lines, nasolabial folds and dynamic lines; Provides natural movement. Its effectiveness is 9-12 months.
• Restylane Kysse: Special for low-medium molecular weight lip filler, G' ~150 Pa, lip volume and contour filler. Its effectiveness is 9-12 months.
• Restylane Lyft: Medium-high molecular weight, G' ~250 Pa, malar and mandibular contour, chin definition, nasolabial fold filler. Its effectiveness is 12-18 months.
• Restylane Defyne: Medium-high molecular weight, G' ~200 Pa, for mid-zone filler, dynamic lines and contour enhancement; The structure offers a combination of resistance and movement. Its effectiveness is 12-18 months.
• Restylane Volyme: Ultra-high molecular weight, G' ~350-400 Pa, deep volumetric filler is used for malar bone, chin volume and facial asymmetry correction. Its effectiveness is 12-18 months.

Teosyal is made by the Swiss company Teoxane and uses CPM (Coherent Polydensified Matrix) technology and Resilience™ technology; It offers a combination of medium-high cohesiveness and smooth action:

• Teosyal Redensity I: Ultra-low molecular weight, serum formula, for skin moisturizing, fine line and skin radiance improvement. Its effectiveness lasts 3-6 months.
• Teosyal Kiss: Low molecular weight lip formula offers natural fullness in lip filler and contour filler. Its effectiveness is 6-9 months.
• Teosyal Deep Lines: Medium molecular weight, for filler medium-deep lines, nasolabial fold and marionette lines. Its effectiveness is around 12 months.
• Teosyal RHA 1/2/3/4 Series: RHA (Resilient Hyaluronic Acid) dynamic HA formulation features Natural Series technology. RHA 1 low, RHA 2 medium, RHA 3 medium-high, RHA 4 high molecular weight; It provides flawless movement in dynamic expression lines and contour filler. Its effectiveness is 12-15 months.
• Teosyal Ultra Plus: High molecular weight, volumetric filler provides strong lift and structure in malar contour, chin and mandibular angle filler. Its effectiveness is 12-18 months.

Made by Belotero Merz, it uses Coherent Polydensified Matrix (CPM) and balanced cross-linking technology to produce the softest, most natural-resulting fillers in the industry:

• Belotero Soft: Ultra-low molecular weight, G' ~60 Pa, for lip fine line and skin moisturizing. Its effectiveness is 6-9 months.
• Belotero Balance: Medium molecular weight, G' ~120 Pa, multi-purpose use in middle area filler, nasolabial fold, thin-medium lines. Provides natural look and movement. Its effectiveness is 9-12 months.
• Belotero Intense: Medium-high molecular weight, G' ~150 Pa, in deep lines, mandibular contour and volume filler. Its effectiveness is around 12 months.
• Belotero Volume: High molecular weight, G' ~200 Pa, for malar bone, chin volume, facial asymmetry and volumetric filler. Its effectiveness is 12-15 months.

Rheology Parameters and Regional Application Guide

Each HA filler is optimized for correct local use, and rheology parameters form the basis of this optimization. Elastic modulus (G') determines stiffness; 5-100 Pa indicates very soft serum formulas (Teosyal Redensity), 100-200 Pa indicates low HA fillers (Juvederm Volbella, Restylane Silk), 200-350 Pa indicates medium fillers (Juvederm Ultra, Restylane Lyft), 350-600+ Pa indicates high fillers (Juvederm Voluma, Restylane Volyme). The cohesiveness parameter is measured by the Gavard-Sundaram test and shows the adhesion of the gel in the tissue and its dispersion resistance. While high cohesiveness is preferred for volumetric fillers, low cohesiveness is used in fine lines and serum fillers. Tan delta (G''/G' ratio) indicates elastic-viscous balance; low tan delta means elastic fillers (structure resistance), high tan delta means viscous fillers (movement and fluidity).

In lip filler: Low molecular weight (500-1500 kDa), G' 80-150 Pa, low tan delta are preferred. Options such as Juvederm Volbella and Restylane Silk/Kysse adapt to the high mobility of the lip. Excessive hard filler creates an artificial or movement-restricted appearance. A slightly thicker product (G' 150-200 Pa) is selected for contour filler.

In the under-eye (periorbital) area: Low-medium molecular weight (600-1500 kDa), G' 80-180 Pa, serum-like consistency is preferred. Due to the thin skin and high vascularity of the eye area, hard fillers increase the risk of sweetness, edema and nodules. Juvederm Ultra XC, Restylane Refyne/Silk are ideal options. A dermal injection depth of 2-3 mm is required to prevent the Tyndall effect.

On fine lines (forehead, glabella, perioral): Medium molecular weight (1000-1800 kDa), G' 150-250 Pa, balanced elasticity are preferred. Products such as Juvederm Ultra, Restylane Refyne, Belotero Balance fill fine lines and do not limit facial movements. Botulinum toxin combination is more effective in dynamic lines.

For midface (malar/zygomatic area) filler: Medium-high molecular weight (1500-2500 kDa), G' 250-400 Pa, high cohesiveness are preferred. Juvederm Ultra Plus, Restylane Lyft, Teosyal Deep Lines are used for malar bone contouring and facial angle improvement. Subperiosteal injection onto the bone structure provides a longer duration of action.

For chin and mandibular contour filler: High molecular weight (2000+ kDa), G' 350-600+ Pa, maximal cohesiveness and lift capacity are preferred. Juvederm Voluma XC, Restylane Volyme, Teosyal Ultra Plus are chosen for chin definition, mandibular angle sharpness and deep volumetric filler. It maximizes injection effectiveness with the subperiosteal technique.

Deep volumetric filler (cheek augmentation, facial re-contouring): Ultra-high molecular weight (2500-3500 kDa), G' 500-600+ Pa, maximal hardness and lift capacity are preferred. Products such as Juvederm Voluma, Restylane Volyme are injected deep into the bone structure; It provides long-term results (18-24 months) in regional stability and volume loss correction. Technical difficulty is high; Knowledge of angiology is essential.

Rheology mismatch is rare and may cause aesthetic problems when hard fillers are used; For example, if volumetric filler is injected into the lips, loss of lip movement and an artificial appearance will occur. Similarly, filler that is too soft will not provide sufficient firmness or lift in the chin filler.

Indications

Static lines are permanent lines seen when facial expressions are not made, and perioral eye contours are forehead and body lines. Line depth decreases due to the filler effect of HA fillers. Volume loss and skin deficiency is the loss of volume in the face after aging, abnormal fat loss, and trauma. Lip shaping is lip vermillion widening, lip edge highlighting, pouty lip creation. Under-eye filler relieves lines and reduces puffiness, corrects volume loss and reduces the aged appearance. Contour improvement is the definition of chin club bone nose chin tip mandibular angle. It is the filler of pit scars such as scar depression, acne scratches, pox scars, surgical scars. Skin moisturizing and hydration is preferred in dehydrated skin and very fine lines. HA is injected intradermally, improving skin hydration and radiance.

Contraindications

Pregnancy and breastfeeding are FDA category C and safety data are insufficient. Injection is postponed if there is active infection, skin infection, herpetic lesion, Lyme disease, active dermatitis at the injection site. Autoimmune diseases, systemic lupus, scleroderma, Sjögren's syndrome, may show hypersensitivity to HA filler. NSAIDs and anticoagulants have a risk of hematoma. A history of allergic reactions to HA or other polymers is rare but has been reported.

Duration of Effect and Recovery

Low molecular weight HA is effective for six to nine months. Medium molecular weight HA is effective for nine to twelve months. High molecular weight HA is effective for twelve to eighteen months. Edema is normal for the first forty-eight to seventy-two hours after the injection. It decreases significantly on the third day. It is completed after seven days. It has a shorter duration of action in high mobility areas such as lips and under the eyes. It has a longer duration of action in static areas such as the chin. Subcutaneous periosteal injection provides longer life.

Metabolism and Breakdown

HA is a natural biopolymer and is completely biodegradable and biocompatible in the body. Metabolic clearance of HA occurs by three main mechanisms:

1. Enzymatic degradation: Hyaluronidase (hyaluronic acid-specific hydrolase) breaks down the HA chain and turns it into disaccharides and monomers. Pure, uncrosslinked HA breaks down very quickly; Its half-life in the dermal layer is 12-24 hours. Hyaluronidase activity is reduced in cross-linked HA; BDDE-crosslinked HA is more resistant to hyaluronidase, DVS-crosslinked HA is intermediately resistant. As the cross-linking density increases, enzymatic degradation slows down; Highly cross-linked The dermal residence time of highly cross-linked HA can be 3-6 months or longer.

2. Fibroblast-mediated endocytosis and intracellular degradation: Fibroblasts and macrophages take the HA gel into the cell by endocytosis (receptor-mediated endocytosis, mediated by CD44). Within the cell, lysosomatic enzymes (various hydrolases and hyaluronidase) convert HA into disaccharides and monomers. This process is a slower dynamic metabolic catabolism pathway and occurs on a weekly time scale.

3. Reactive oxygen species (ROS)-mediated oxidative degradation: Fibroblast metabolism and macrophage activation produce reactive oxygen species (ROS: superoxide, hydroxyl radical, hydrogen peroxide). ROS subject the HA chain to oxidative degradation; Direct HA-ROS interaction or ROS-stimulated radical reactions lead to HA chain scission. This mechanism is accelerated in local inflammation and may shorten the residence time of cross-linked HA.

Safety profile of BDDE cross-linking: BDDE (1,4-butanediol diglycidyl ether) is a crosslinking agent patented by Allergan. BDDE is completely metabolized after chemical binding; The product has no BDDE residue in the final HA-BDDE adduct. HA disaccharide units are covalently bonded with BDDE, forming a gel structure. There is no BDDE toxicity after injection. During the degradation of cross-linked HA, BDDE metabolites (glucuron acid, glycerol conjugate) are excreted, and no toxic accumulation is observed. FDA and EMA safety data have confirmed that BDDE HA fillers do not cause systemic toxicity and genetic toxicity (mutagenicity, carcinogenicity).

Effect of cross-linking density on longevity: High cross-link density (HCC) provides a longer duration of effectiveness (15-18 months) hardening the HA gel; but rheology can be solid. Low cross-link density (LCC) provides a softer, more natural gel but short effectiveness (6-9 months). Medium cross-linking provides balanced dead-end emergence (9-12 months effectiveness, good rheology). Producer selection is optimized based on clinical goals.

Cumulative anti-aging effects: Periodic HA injections (repeated every 3-4 months) may have limited cumulative effects. HA injections stimulate peripheral fibroblast activation; increases collagen type 1 and 3 synthesis, increases TIMP-1 expression (protection of ECM by matrix metalloproteinase inhibition). After long-term periodic HA fillers, skin quality improvement, increased hydration and elasticity gain can be observed. These cumulative effects are due to endogenous collagen stimulation of fibroblast activation rather than the original filler HA itself.

Risks and Side Effects

Common and mild side effects (prevalence <5%): Injection site reactions consist of local redness, swelling, and minimal pain or discomfort; It usually regresses spontaneously within 24-48 hours. Hematoma (bruising) and ecchymosis are common with blunt injections or in anticoagulant users; Hirudin or arnica treatment helps in acceleration. Edema (fluid accumulation) is normal in the first 72 hours and is reduced by the use of steroid cream and cold application.

Rare side effects (prevalence <0.1%): Tyndall effect is the optical phenomenon of superficial HA injection; Because HA particles scatter light, they create a bluish-brown appearance, typically seen in the under-eye area. Precaution is injection at a dermal depth of 2-3 mm. We dissolve the treatment with hyaluronidase injection. nodule formation It may be due to aseptic granulomatous reaction, biofilm formation, or poor quality product endotoxins. The nodule may be palpable, painful, or discolored; Spontaneous absorption may occur in 3-6 months, and hyaluronidase helps in persistent nodules. Granulomatous reaction or FBR (foreign body reaction) skin system detects HA as a foreign substance and responds with epithelioid macrophage, giant cells and collagen formation; It is a rare, delayed reaction and is diagnosed with intradermal tests (patch testing). asymmetry It may be caused by incorrect injection technique, dose incompatibility or asymmetric skin structure; slight asymmetry is natural and tolerable, significant asymmetry requires hyaluronidase injection and revision.

Vascular complications (Vascular Occlusion) — Serious and potential black complication of HA injection: The mechanism occurs by intravascular HA injection (direct contact with the vessel) or extravascular high pressure injection (pressurizing the vessel from the outside). Risk is graded according to the target vessel:

• Glabellar region high risk: Superficial injection onto the supratrochlear and supraorbital arteries may cause vision loss through embolism and ophthalmic artery retrograde embolism. It has close to zero fault tolerance.
• Nasolabial fold medium-high risk: Lateral nasal artery injection or high pressure may cause nasal ischemia and skin necrosis.
• Temporal region medium risk: Superficial temporal artery injection temporal area ischemia risk.
• Lip and perioral low-moderate risk: Superior and inferior labial arteries are thin in size, there is technical difficulty in injection.

Clinical progression and degree of severity of vascular occlusion:

• Early finding (0-5 minutes): Abnormal paleness, livedo reticularis (reticular discoloration), hypoperfusion defined by dermatome border, pain or unusual sensation in the patient.
• Third stage (5-30 minutes): Blanching, loss of skin temperature, increased edema, extravascular halo (redness around the white area).
• Fourth stage (30 minutes-2 hours): Livedo reticularis intensification, dark blue-black discoloration of the skin, granulation in the form of a rash, onset of tínea or skin thickening.
• Fifth stage (after 2-6 hours): Onset of necrosis, skin darkening, risk of gangrene, rapid increase in pain, precursor to infection.
• Final stage (6-48 hours and later): Risk of tissue necrosis, keloid scar, permanent deformity and loss of function. If spontaneous epithelization does not progress after 2-3 months, surgical revision may be required after scarring.

Emergency treatment of vascular occlusion (within 2-6 hours after injection): Stop the procedure immediately. Topical and/or intradermal injection of oxygen and nitroglycerin provides vasodilation. Hyaluronidase 500-1500 U is injected into the injection site and from the area into the environment; It restores circulation by breaking down HA. Aspirin 500 mg, dextran IV, pentoxifylline pen improve blood flow. Hot compress increases blood flow, cold application can deepen isemia. Immediate neuroophthalmology or vascular surgery consultation is essential in cases of suspected ophthalmic artery embolism; Very rare central retinal artery embolism requires anterior chamber paracentesis or fibrinolytic therapy. If orbital compartment syndrome occurs and is severe, lateral canthotomy surgical drainage may be required.

Embolism — Submicroscopic form of vascular occlusion: HA micro-granules enter the systemic circulation, causing occlusion of distal arteries (pulmonary embolism, stroke, myocardial infarction are rare but common). The risk increases with external pressure injection, multi-pass technique and high concentration fillers.

Infection complications: cellulitis (local bacterial infection) begins 48 hours post-injection, shows redness, heat, water impermeability; Treatment with topical + systemic antibiotics. Abscesso (inflammation muscle bag) deeper formation, incision and drainage may be required. Necrotizing fasciitis (rapid necrosis of fascia) extremely rare but fatal; Very rapid progression to systemic symptoms, diagnosis is made with LRINEC score >6, urgent surgical debridement is life-saving. The risk of infection is minimized by sterile injection technique and appropriate asepsis.

Hyaluronidase: Recycling HA Fillers

If the results of HA filler are not satisfactory or serious side effects occur, the physician may perform hyaluronidase injection. Hylenex recombinant human hyaluronidase is FDA approved. Vitrase testicular hyaluronidase is made by ISTA Pharmaceuticals. Hyaluronidase breaks down the HA chain. Pure HA breaks down immediately. Cross-linked HA breaks down more slowly. Ninety plus percent disintegration is achieved in the first forty-eight hours, sixty to seventy percent disintegration after two weeks, and thirty to forty percent disintegration after one month.

Alternatives and Combination Therapies

Calcium hydroxyapatite Radiesse is a biocompatible mineral. It is thicker than HA and lasts for twelve to eighteen months. Poly-L-lactic acid Sculptra is a biodegradable polyester and has long effectiveness. Autologous fat is the patient's own fat; it is permanent but has a high risk of resorption. The combination of HA and Botulinum Toxin controls HA volume botox dynamic lines. Combination of HA and Radiofrequency, RF microneedling is applied after HA injection. Combination of HA and Chemical Peel: Superficial chemical peel is applied after HA filler. The combination of HA and Microneedling deepens HA penetration in the microneedling channel. Combination of HA and Lip Lift Surgical lip lift is applied before or after HA lip filler.

Frequently Asked Questions

Detailed questions and answers are provided below.

Dr. Hamza Gemici Comment

"Hyaluronic acid is considered the gold standard product in dermal fillers. In my clinical experience as a physician, the Juvederm and Restylane series have given the most reliable results for years. While product selection is critical, it may be necessary to use Volbella soft low molecular weight on the lips of a patient, while Voluma hard high molecular weight is used on the chin of the same patient. Hyaluronidase rescue injection, although rare, has been very valuable in correcting side effects. The most important point requires awareness of the risk of vascular occlusion and injection awareness."

— Op. Dr. Hamza Gemici

Resources and References

This content has been prepared based on international peer-reviewed medical literature, FDA product monographs and EMA technical documentation.

Last update: 21 April 2026 · Medical editor: Op. Dr. Hamza Gemici